Therapeutic potential of cannabinoids in neurological conditions: a systematic review of clinical trials
OverviewCannabinoids have gained increasing attention for their therapeutic potential in treating several neurological conditions, including neurodegenerative diseases, chronic pain, and epilepsy. This review aims to assess the current clinical trials investigating cannabinoids, primarily Tetrahydro...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1521792/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832087081489268736 |
|---|---|
| author | Alqassem Y. Hakami Alqassem Y. Hakami Fahad S. Alshehri |
| author_facet | Alqassem Y. Hakami Alqassem Y. Hakami Fahad S. Alshehri |
| author_sort | Alqassem Y. Hakami |
| collection | DOAJ |
| description | OverviewCannabinoids have gained increasing attention for their therapeutic potential in treating several neurological conditions, including neurodegenerative diseases, chronic pain, and epilepsy. This review aims to assess the current clinical trials investigating cannabinoids, primarily Tetrahydrocannabinol and Cannabidiol, for neurological disorders. This review will aim to highlight the efficacy, safety, and outcome measures used in these trials.MethodsClinical trials were identified using ClinicalTrials.gov, focusing on studies that examined the effects of cannabinoids in treating neurological conditions. All trials that fulfilled the following criteria were included: Phase 1–4, focused on cannabinoids as primary intervention, and measured relevant outcomes such as pain relief, cognitive function, or spasticity reduction. Data on conditions, interventions, primary and secondary outcomes, and trial phases were extracted and analysed.ResultsA total of 47 clinical trials were identified, including different neurological conditions. The most frequently studied conditions were Multiple Sclerosis, Fibromyalgia, and Parkinson’s Disease. Most trials were in Phase 2, with the primary outcome measures focused on pain management, spasticity, and cognitive function. Secondary outcomes included safety and tolerability measures.ConclusionThe review highlights the broad therapeutic potential of cannabinoids in neurology, with promising results in symptom management for conditions like Multiple Sclerosis and Fibromyalgia. However, the lack of standardized study protocols, dosing, and outcome measures presents challenges for broader clinical implementation.Systematic Review Registrationclinicatrials.gov. |
| format | Article |
| id | doaj-art-0705513d1a1a41258bfa8af6f23ee78b |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-0705513d1a1a41258bfa8af6f23ee78b2025-02-06T07:09:26ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-02-011610.3389/fphar.2025.15217921521792Therapeutic potential of cannabinoids in neurological conditions: a systematic review of clinical trialsAlqassem Y. Hakami0Alqassem Y. Hakami1Fahad S. Alshehri2College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi ArabiaKing Abdullah International Medical Research Center, Jeddah, Saudi ArabiaDepartment of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi ArabiaOverviewCannabinoids have gained increasing attention for their therapeutic potential in treating several neurological conditions, including neurodegenerative diseases, chronic pain, and epilepsy. This review aims to assess the current clinical trials investigating cannabinoids, primarily Tetrahydrocannabinol and Cannabidiol, for neurological disorders. This review will aim to highlight the efficacy, safety, and outcome measures used in these trials.MethodsClinical trials were identified using ClinicalTrials.gov, focusing on studies that examined the effects of cannabinoids in treating neurological conditions. All trials that fulfilled the following criteria were included: Phase 1–4, focused on cannabinoids as primary intervention, and measured relevant outcomes such as pain relief, cognitive function, or spasticity reduction. Data on conditions, interventions, primary and secondary outcomes, and trial phases were extracted and analysed.ResultsA total of 47 clinical trials were identified, including different neurological conditions. The most frequently studied conditions were Multiple Sclerosis, Fibromyalgia, and Parkinson’s Disease. Most trials were in Phase 2, with the primary outcome measures focused on pain management, spasticity, and cognitive function. Secondary outcomes included safety and tolerability measures.ConclusionThe review highlights the broad therapeutic potential of cannabinoids in neurology, with promising results in symptom management for conditions like Multiple Sclerosis and Fibromyalgia. However, the lack of standardized study protocols, dosing, and outcome measures presents challenges for broader clinical implementation.Systematic Review Registrationclinicatrials.gov.https://www.frontiersin.org/articles/10.3389/fphar.2025.1521792/fullneurodegenerativeneurologicaltetrahydrocannabinolcannabidiolclinical trials |
| spellingShingle | Alqassem Y. Hakami Alqassem Y. Hakami Fahad S. Alshehri Therapeutic potential of cannabinoids in neurological conditions: a systematic review of clinical trials Frontiers in Pharmacology neurodegenerative neurological tetrahydrocannabinol cannabidiol clinical trials |
| title | Therapeutic potential of cannabinoids in neurological conditions: a systematic review of clinical trials |
| title_full | Therapeutic potential of cannabinoids in neurological conditions: a systematic review of clinical trials |
| title_fullStr | Therapeutic potential of cannabinoids in neurological conditions: a systematic review of clinical trials |
| title_full_unstemmed | Therapeutic potential of cannabinoids in neurological conditions: a systematic review of clinical trials |
| title_short | Therapeutic potential of cannabinoids in neurological conditions: a systematic review of clinical trials |
| title_sort | therapeutic potential of cannabinoids in neurological conditions a systematic review of clinical trials |
| topic | neurodegenerative neurological tetrahydrocannabinol cannabidiol clinical trials |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1521792/full |
| work_keys_str_mv | AT alqassemyhakami therapeuticpotentialofcannabinoidsinneurologicalconditionsasystematicreviewofclinicaltrials AT alqassemyhakami therapeuticpotentialofcannabinoidsinneurologicalconditionsasystematicreviewofclinicaltrials AT fahadsalshehri therapeuticpotentialofcannabinoidsinneurologicalconditionsasystematicreviewofclinicaltrials |